HK-listed Genscript Biotech unit Probio to raise $150m from Hillhouse Capital

HK-listed Genscript Biotech unit Probio to raise $150m from Hillhouse Capital

Laboratory equipment. Photo: Pixabay

Probio Cayman, a subsidiary of Hong Kong-listed Genscript Biotech, has entered into an agreement to raise about $150 million from private equity firm Hillhouse Capital Group, the parent firm disclosed in a filing with the Hong Kong stock exchange on Thursday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter